Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bausch Health Companies (NYSE:BHC) is the #1 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bausch Health Companies (NYSE:BHC) is: Value: A, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: C, and AI: B.

Bausch Health Companies (NYSE:BHC) has a Due Diligence Score of 9, which is -18 points lower than the healthcare sector average of 27. Although this number is below the industry average, our proven quant model rates BHC as a "A".It passed 3 out of 33 due diligence checks and has weak fundamentals. Bausch Health Companies has seen its stock return 19.53% over the past year, overperforming other healthcare stocks by 117 percentage points.

Bausch Health Companies has an average 1 year price target of $9.00, an upside of 10.57% from Bausch Health Companies's current stock price of $8.14.

Bausch Health Companies stock has a consensus Hold recommendation according to Wall Street analysts. Of the 2 analysts covering Bausch Health Companies, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Puma Biotechnology (NASDAQ:PBYI) is the #2 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: B.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 48, which is 21 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 102.78% over the past year, overperforming other healthcare stocks by 201 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -41.29% from Puma Biotechnology's current stock price of $10.22.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Regeneron Pharmaceuticals (NASDAQ:REGN) is the #3 top healthcare stock out of 1051 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Regeneron Pharmaceuticals (NASDAQ:REGN) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a Due Diligence Score of 47, which is 20 points higher than the healthcare sector average of 27. It passed 18 out of 38 due diligence checks and has strong fundamentals. Regeneron Pharmaceuticals has seen its stock return 51.55% over the past year, overperforming other healthcare stocks by 149 percentage points.

Regeneron Pharmaceuticals has an average 1 year price target of $904.29, a downside of -7.1% from Regeneron Pharmaceuticals's current stock price of $973.36.

Regeneron Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 24 analysts covering Regeneron Pharmaceuticals, 58.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 33.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 80 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 34.8%, which is 32 percentage points higher than the healthcare sector average of 2.98%.

Cumberland Pharmaceuticals's dividend payout ratio of -411% indicates that its high dividend yield might not be sustainable for the long-term.

Indivior Pharmaceuticals (NASDAQ:INDV) has an annual dividend yield of 28.88%, which is 26 percentage points higher than the healthcare sector average of 2.98%.

Indivior Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Supernus Pharmaceuticals (NASDAQ:SUPN) has an annual dividend yield of 28.88%, which is 26 percentage points higher than the healthcare sector average of 2.98%.

Supernus Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.63% in the last day, and up 1.07% over the last week. Pasithea Therapeutics was the among the top gainers in the healthcare sector, gaining 44.02% yesterday.

Pasithea Therapeutics shares are trading higher after the company announced the FDA clearance of its IND application for a Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 88.17% in the past year. It has overperformed other stocks in the healthcare sector by 186 percentage points.

Embecta (NASDAQ:EMBC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -54.69% in the past year. It has overperformed other stocks in the healthcare sector by 43 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 26.22% in the past year. It has overperformed other stocks in the healthcare sector by 124 percentage points.

58.15% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 36.71% over the next year.

4.1% of healthcare stocks have a Zen Rating of A (Strong Buy), 13.72% of healthcare stocks are rated B (Buy), 48.46% are rated C (Hold), 25.9% are rated D (Sell), and 7.82% are rated F (Strong Sell).